UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study

American journal of respiratory and critical care medicine, 2011-11, Vol.184 (10), p.1125-1132

2011

Volltextzugriff (PDF)

Fully automated endoscopic disease activity assessment in ulcerative colitis

Gastrointestinal endoscopy, 2021-03, Vol.93 (3), p.728-736.e1

2021

Volltextzugriff (PDF)

Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.456-463.e3

2012

Volltextzugriff (PDF)

Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome

The Journal of clinical investigation, 2022-02, Vol.132 (3), p.1-7

2022

Volltextzugriff (PDF)

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Clinical cancer research, 2019-06, Vol.25 (12), p.3508-3516

2019

Volltextzugriff (PDF)

Hypereosinophilic syndrome: An update

American journal of hematology, 2005-10, Vol.80 (2), p.148-157

2005

Volltextzugriff (PDF)

Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study

European urology, 2006-11, Vol.50 (5), p.1086-1095

2006

Volltextzugriff (PDF)

Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double‐blind, 12‐week, flexible‐dose, placebo‐controlled erectile dysfunction clinical trial

BJU international, 2004-12, Vol.94 (9), p.1301-1309

2004

Volltextzugriff (PDF)

Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome

The Journal of clinical investigation, 2022-02, Vol.132 (3)

2022

Volltextzugriff (PDF)

Abstract CT132: Safety and dose selection for LYC-55716, a first-in-class RORγ agonist to treat solid tumors: Phase I results from an open-label, multicenter Phase I/IIa trial

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT132-CT132

2018

Volltextzugriff (PDF)

A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS9111-TPS9111

2018

Volltextzugriff (PDF)

Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5566-5566

2018

Volltextzugriff (PDF)

Emerging therapeutic targets in psoriasis

Current opinion in pharmacology, 2004-06, Vol.4 (3), p.306-310

2004

Volltextzugriff (PDF)

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.424-424

2018

Volltextzugriff (PDF)

RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.171-171

2018

Volltextzugriff (PDF)

Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.67-67

2018

Volltextzugriff (PDF)

Erectile response to vardenafil in men with a history of nonresponse to sildenafil: A time-from-dosing descriptive analysis

Clinical therapeutics, 2005-09, Vol.27 (9), p.1452-1461

2005

Volltextzugriff (PDF)

A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS2617-TPS2617

2018

Volltextzugriff (PDF)

Reslizumab in Children and Adolescents With Eosinophilic Esophagitis: Results of a Double-Blind, Randomized, Placebo-Controlled Study

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-136-S-136

2011

Volltextzugriff (PDF)

Extended duration of efficacy of vardenafil when taken 8 hours before intercourse : A randomized, double- blind, placebo- controlled study. Commentary

European urology, 2006, Vol.50 (5), p.1086-1095

2006

Volltextzugriff (PDF)

Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. Commentary

BJU international, 2004, Vol.94 (9), p.1301-1309

2004

Volltextzugriff (PDF)

Developing a successful medical group

Family practice management, 1999-06, Vol.6 (6), p.27-31

1999

Volltextzugriff (PDF)

Physician-owned groups: the best strategy for success

Family practice management, 1999-05, Vol.6 (5), p.38-41

1999

Volltextzugriff (PDF)

Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial

PloS one, 2017-02, Vol.12 (2), p.e0170547-e0170547

2017

Volltextzugriff (PDF)

Acellular Dermal Matrix in Immediate Expander/Implant Breast Reconstruction: A Multicenter Assessment of Risks and Benefits

Plastic and reconstructive surgery (1963), 2017-12, Vol.140 (6), p.1091-1100

2017

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(106)

Publikationsform

Artikel
(120)
Bücher
(2)

Sprache

Englisch
(121)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study

Fully automated endoscopic disease activity assessment in ulcerative colitis

Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial

Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Hypereosinophilic syndrome: An update

Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study

Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double‐blind, 12‐week, flexible‐dose, placebo‐controlled erectile dysfunction clinical trial

Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome

Abstract CT132: Safety and dose selection for LYC-55716, a first-in-class RORγ agonist to treat solid tumors: Phase I results from an open-label, multicenter Phase I/IIa trial

A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer

Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies

Emerging therapeutic targets in psoriasis

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion

RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation

Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion

Erectile response to vardenafil in men with a history of nonresponse to sildenafil: A time-from-dosing descriptive analysis

A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors

Reslizumab in Children and Adolescents With Eosinophilic Esophagitis: Results of a Double-Blind, Randomized, Placebo-Controlled Study

Extended duration of efficacy of vardenafil when taken 8 hours before intercourse : A randomized, double- blind, placebo- controlled study. Commentary

Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. Commentary

Developing a successful medical group

Physician-owned groups: the best strategy for success

Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial

Acellular Dermal Matrix in Immediate Expander/Implant Breast Reconstruction: A Multicenter Assessment of Risks and Benefits

Suchergebnisse filtern